Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the HER2 desk.
health
In the phase 2 PHERGain trial, a PET- and pathology-guided strategy had an estimated five-year invasive disease-free survival of 89.5% among patients assigned to the adaptive-treatment group who underwent surgery. Exploratory ctDNA analyses linked early clearance with higher pathological complete response rates and better five-year outcomes.
health
A Danish nationwide screening effort found conventional HER2-positive status in 62 of 806 people with esophageal squamous cell carcinoma. In a small phase II trial, trastuzumab-based treatment showed responses, while tissue mapping found HER2-poor fibrotic areas enriched for B7-H3.
health
In a randomized phase 2 trial, evorpacept plus trastuzumab, ramucirumab and paclitaxel produced higher response rates than the same regimen without evorpacept. The trial met its prespecified response-difference threshold between treatment arms, but not its statistical target against a historical benchmark.
health
A South Korean phase 1b/2 trial found a 55% objective response rate when trastuzumab and nivolumab were added to gemcitabine and cisplatin for previously untreated HER2-positive advanced biliary tract cancer. The single-arm results provide early evidence for first-line HER2-targeted chemoimmunotherapy, while randomized confirmation is still needed.